Special Issue "Next Generation of PLGA-Based Nanoparticles as Drug Delivery Systems for Biomedical Applications"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 10 May 2024 | Viewed by 620

Special Issue Editors

School of Pharmacy, University of Camerino, 62032 Camerino, Italy
Interests: drug delivery formulations; polymeric nanoparticles; functionalization of biocompatible polymers; nanotechnology

Special Issue Information

Dear Colleagues,

This Special Issue is dedicated to advanced PLGA-based nanotechnology research on biomedical applications.

The development of novel and cutting-edge treatments for disease is a relevant health matter on a global scale. As a result, we are constantly researching safe therapies and medications that can precisely target the site of diseases with the optimal duration of action, minimal side effects, and an ideal pharmacokinetic profile. Over the last few decades, polymeric nanoparticles used in the drug delivery field have successfully addressed most of these therapeutic objectives. Poly (lactic-co-glycolic acid) (PLGA) is a type of medical polymer that is most commonly used due to its excellent biocompatibility and tunable degradation and release properties. It is also a versatile vehicle for transporting different types of drugs, including those that are hydrophobic or hydrophilic, small molecules or macromolecules, and protects them from degradation and uncontrolled release. In addition, PLGA-based nanoparticles can have their surface characteristics modified to enhance interactions with biological substrates. Moreover, they may be conjugated with target molecules to reach particular organs, tissues, or cells. They have been used for various medical applications, from vaccinations to therapies for cancer, neurological problems, inflammation, and other illnesses. There are several biomedical applications for PLGA-based nanoparticles, and the number of these is expected to rise as technology progresses.

Here, we focus on the latest advanced PLGA-based nanoparticles used in the biomedical field. This issue will include contributions of research applications on the technologies available for producing and analyzing PLGA nanoparticles, with a focus on novel biomedical applications and the most up-to-date scalability PLGA-based nanoparticle formulation methods.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • PLGA nanocarriers for cancer targeting;
  • PLGA nanocarriers for immunomodulation and vaccine formulations;
  • PLGA nanocarriers for inflammatory disorders;
  • Scalable fabrication techniques for polymeric nanoparticles;
  • Antibiotic resistance;
  • Theranostic applications.

I look forward to receiving your contributions.

Prof. Dr. Piera Di Martino
Dr. Maria Rosa Gigliobianco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • nanoparticles
  • drug delivery systems
  • PLGA
  • targeting
  • formulation techniques
  • encapsulation
  • polymer

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


18 pages, 4156 KiB  
Polymeric Particle BAM15 Targeting Macrophages Attenuates the Severity of LPS-Induced Sepsis: A Proof of Concept for Specific Immune Cell-Targeted Therapy
Pharmaceutics 2023, 15(12), 2695; https://doi.org/10.3390/pharmaceutics15122695 - 28 Nov 2023
Viewed by 280
Macrophage polarization requires different energy sources and metabolic processes. Therefore, cell energy interference to alter macrophage functions has been proposed as a treatment for severe inflammatory diseases, including sepsis. In this study, targeting cell energy using BAM15 (a mitochondrial uncoupling agent) in human [...] Read more.
Macrophage polarization requires different energy sources and metabolic processes. Therefore, cell energy interference to alter macrophage functions has been proposed as a treatment for severe inflammatory diseases, including sepsis. In this study, targeting cell energy using BAM15 (a mitochondrial uncoupling agent) in human THP-1 and mouse RAW264.7 macrophages prominently interfered with M1 but not M2 polarization. Free BAM15 (BAM15) and BAM15-loaded PLGA particles (BAM15 particles) reduced the inflammatory response of M1 macrophages and enhanced the expression of M2 signature genes with the restoration of mitochondrial activity (extracellular flux analysis) in RAW264.7 cells. Furthermore, BAM15 particles but not BAM15 showed specific effects on the inflammatory response of macrophages but not neutrophils, and the particles were actively captured by splenic and liver macrophages in vivo. Administration of BAM15 and BAM15 particles attenuated the severity of sepsis in LPS-induced sepsis mice. Interestingly, BAM15 particles but not BAM15 alleviated LPS-induced liver injury by reducing hepatic inflammation. Our findings substantiate the superior efficacy of macrophage-targeted therapy using a BAM15 particle-delivery system and provide further support for clinical development as a potential therapy for severe inflammatory diseases. Full article
Show Figures

Figure 1

Back to TopTop